hepatitis C | oncology | Anadys Pharmaceuticals, Inc.

2/2/2010
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

1/22/2010
ANADYS PHARMACEUTICALS PROVIDES PROGRESS UPDATE

Anadys Presenting at the 12th Annual BIO CEO & Investor Conference
Tuesday, February 9, 2010 at 10:00 am ET

Anadys Presenting at the 30th Annual Cowen and Company Healthcare Conference
Monday, March 8, 2010 at 1:45pm ET

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.		ANA598 - HCV ANA773 - HCV ANA773 - Oncology
Home \| About Us \| Therapeutic Focus \| Development Programs \| Investors \| Careers \| Contact Us Terms of Use \| Privacy Policy \| Site Map © Anadys Pharmaceuticals, Inc.